Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-Maintenance
jRCT2031230223Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of iberdomide and lenalidomide in multiple myeloma (MM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Jul 2023; status: active, not recruiting.
02
Drugs
iberdomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031230223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230223.